secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0000950170-23-007580
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx reports $22.2M full-year product revenue; net loss $198.4M
-----------------------------------------------------------------

- Q4 net product revenue $21.9M; full-year 2022 net product revenue $22.2M from RELYVRIO/ALBRIOZA sales.
- Net loss for 2022 was $198.4M ($3.39 per share) vs. $87.9M in 2021; cash & short-term investments $346.9M.
- Phase 3 PHOENIX trial fully enrolled (664 participants); topline data expected mid-2024.
- EU MAA regulatory review ongoing; company now expects CHMP opinion mid-2023 and decision Q3 2023 at earliest.
- Karen Firestone appointed to Board of Directors effective March 16; raised $230.6M net in October 2022 public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/0000950170-23-007580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/amlx-20230313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer